CD160 and cancer: In previous studies, CD244 has already been shown to be co-expressed on CD8+ T-cells with other immunoregulatory receptors, including PD-1, CD160, CTLA-4, and TIM-3 in both mouse cancer models and patients with cancer [56,57,58,59].